BOSTON, Sept. 30 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce the results of the 2010 annual shareholder meeting held September 28, 2010 near Solos' headquarters in Boston, MA. During Solos' annual shareholder meeting, Robert Segersten, Amanda Segersten and Fred Schiemann were re-elected to serve on the Company's Board of Directors until the next shareholders meeting. The shareholders also approved the motion to retain Fred Schiemann, CPA as the Company's accountant.
As a part of the Company's presentation, Robert Segersten, President of Solos Endoscopy, Inc., outlined the Company's progress in satisfying the requirements for the Company's ISO 13485 quality management system (QMS) initiative. Mr. Segersten restated that Solos has successfully completed Phase One requirements and announced that the Company is diligently working towards completion of Phase Two requirements, which Solos expects to conclude in the next six months. The Company also touched upon the further development and introduction of new products for the fourth quarter.
"We are excited to serve another term on the Board of Directors of Solos. The Company continues to implement its strategy of growth through the development of new products and the eventual introduction of our product globally," stated Robert Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2010 PR Newswire.
All rights reserved